Nabriva's Xenleta (lefamulin) Receives FDA's Approval for the Treatment of Community-Acquired Bacterial Pneumonia in Adults
Shots:
- The US FDA’s approval is based on two P-III studies- LEAP 1 & LEAP 2. LEAP 1 involves assessing of Xenleta (150mg IV/600mg oral for 5-7days) vs moxifloxacin (IV/oral for 7days) with/out linezolid in patients with CABP which demonstrated non-inferiority to moxifloxacin i.e- ECR rate (87.3% vs 90.2%)
- The P-III LEAP 2 study involves assessing of Xenalta (PO for 5days) vs moxifloxacin (PO for 7days) in resulted in achieving similar ECR rates in IIT population
- Xenleta (lefamulin) is a semi-synthetic pleuromutilin antibiotic positioned for use as a 1L therapy for CABP- targeting in vitro spectrum of activity against Gram+ and Gram- pathogens associated CABP and has received FDA’s QIDP & FT designation with its expected availability in mid-Sept’2019
Click here to read full press release/ article | Ref: Nabriva | Image: Pitchbook
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com